Principled by design
We are committed to following these tenets of good business that havehelped shape the Mission, Vision, and Values by which we run SCILEX.
SCILEX Pharmaceuticals responsibly develops and brings branded pharmaceutical products to market using groundbreaking technologies that maximize the quality of life for all.
We are uncompromising in our focus to become the global pharmaceutical leader in pain management. We are committed to social, environmental, economic, and ethical responsibility. Dedicated to using international partnerships, we strive to deliver the next generation of trailblazing products that are responsible by design.
Responsibility: We are determined to relieve pain for all of our stakeholders.
Diversity: We are strengthened by the multiplicity of our experiences, backgrounds, outlooks, and partnerships.
Excellence: We are committed to being part of the solution the right way.
Integrity: When it comes to doing the right thing, we do not compromise.
Quality: Our products are built on a foundation of proven trust.
Accountability: Our outlook is socially, environmentally, economically, and ethically focused.
Experienced by design
Comprising industry veterans and visionary thinkers, the SCILEX Board of Directors is a management team that has decades of pharmaceutical experience with a strong track record of success. The members offer a collective knowledge of drug development, finance, accounting, regulatory, legal, sales, and marketing to help advise and counsel the day-to-day Executive Team.
- Henry Ji, Ph.D
- Jaisim Shah
- Toshinari Hidekuma
- David H. Deming
Henry Ji, Ph.DHenry Ji is the co-founded and has served as a director of Sorrento since January 2006, and as its Chief Executive Officer and President since September 2012.
Dr. Ji served as Sorrento’s Chief Scientific Officer from November 2008 to September 2012 and as its Interim Chief Executive Officer from April 2011 to September 2012.
In 2002, Dr. Ji founded and was President of BioVintage, a biopharmaceutical company. From 2001 to 2002, Dr. Ji served as VP of Strategic Alliances at CombiMatrix, and was responsible for strategic technology alliances. From 1999 to 2001, Dr. Ji served as Director of Business Development, and in 2001 as VP at Stratagene (later acquired by Agilent Technologies), a biotechnology company. In 1997, Dr. Ji co-founded Stratagene Genomics, a wholly-owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer from its founding until 1999.
Dr. Ji obtained his Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University.
Jaisim ShahMr. Shah currently serves as the Chief Executive Officer and board member at Semnur Pharmaceuticals. Prior to Semnur, Mr. Shah was a consultant to several businesses, including Sorrento Therapeutics. From 2011 through 2012, Mr. Shah was the Chief Business Officer of Elevation Pharmaceuticals. Prior to Elevation, Mr. Shah was President of Zelos Therapeutics, where Mr. Shah focused on financing and business development. Prior to Zelos, Mr. Shah was the SVP and Chief Business Officer at CytRx. Previously, Mr. Shah was Chief Business Officer at Facet Biotech and PDL BioPharma where he completed numerous licensing/ partnering and strategic transactions. Prior to PDL, Mr. Shah was at Bristol-Myers Squibb, most recently as Vice President of Global Marketing where he received the “Presidents Award” for completing one of the most significant collaborations in the company’s history. Previously, Mr. Shah was at F. Hoffmann-La Roche in international marketing and was global business leader for corporate alliances with Genentech and Idec. Mr. Shah holds an MA in Economics from the University of Akron and an MBA from University of Oklahoma.
Toshinari HidekumaToshinari Hidekuma has more than twenty years of management experience in the pharmaceutical industry. Mr. Hidekuma currently serves as the pharmaceutical division director and managing executive officer for Itochu Chemical Frontier Corporation (“ICF”), a member of ITOCHU Corporation, a Fortune Global 500 Company and one of the three leading sogo shosha (general trading companies) in Japan. During his tenure at ICF, Mr. Hidekuma built up the pharmaceutical division from scratch, starting with the importing of active pharmaceutical ingredient to supporting the development of branded products. Mr. Hidekuma has worked with products in the areas of pain, oncology and biosimilars and in the markets of Asia, Europe and the US. Prior to ITOCHU, Mr. Hidekuma was engaged in the service of establishing co-development agreements between pharmaceutical companies in Japan and the development of new medicines which are still on the market of Japan. Mr. Hidekuma holds a license of pharmacist degree from Gifu pharmaceutical college in Japan and also spent two years at Golden Gate University in San Francisco, California, studying marketing.
David H. DemingMr. Deming is a banker with TAG Healthcare Advisors, LLC, a boutique financial advisory firm serving the pharmaceutical, biotech and medical device industries. He has over 35 years of banking experience, of which 27 years were with J. P. Morgan, where he ran the healthcare investment banking group for twelve years. Mr. Deming has broad experience in capital raising, mergers and acquisitions, and strategic advice. Mr. Deming is on the Boards of IRX Therapeutics, Inc. and St Johnland Nursing Home, Inc.
Leadership by design
Legal, Finance, Clinical, Regulatory, and Product Commercialization
The mission of the Executive Team is to bolster our proprietary pain management technology by employing years of expertise that comes with overseeing market access, commercialization, advocacy, and government affairs programs. These seasoned professionals bring SCILEX a type of leadership that is unmatched in the pharmaceutical industry.
- Henry Ji, Ph.D.
Chief Executive Officer
- Anthony P. Mack, MBA
Co-Founder and President
- William Pedranti, JD
Co-Founder and COO
- Kevin Herde
Chief Financial Officer
- George Ng, JD
General Counsel and Secretary
Henry Ji, Ph.D.Henry Ji is the co-founded and has served as a director of Sorrento since January 2006, and as its Chief Executive Officer and President since September 2012. Dr. Ji served as Sorrento’s Chief Scientific Officer from November 2008 to September 2012 and as its Interim Chief Executive Officer from April 2011 to September 2012. In 2002, Dr. Ji founded and was President of BioVintage, a biopharmaceutical company. From 2001 to 2002, Dr. Ji served as VP of Strategic Alliances at CombiMatrix, and was responsible for strategic technology alliances. From 1999 to 2001, Dr. Ji served as Director of Business Development, and in 2001 as VP at Stratagene (later acquired by Agilent Technologies), a biotechnology company. In 1997, Dr. Ji co-founded Stratagene Genomics, a wholly-owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer from its founding until 1999. Dr. Ji obtained his Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University.
Anthony P. Mack, MBAAnthony Mack has more than 20 years of experience in the pharmaceutical and finance industries. Prior to co-founding SCILEX Pharmaceuticals, Mr Mack founded Miami’s ProSolus Pharmaceuticals, a 12,000-square-foot R&D and cGMP transdermal manufacturing facility. During his tenure with ProSolus, Mr Mack has overseen agreements with US and international pharmaceutical partners to develop 5 generic transdermal prescriptions. In 2014, ProSolus was awarded the Dade County Life Science Award. Mr Mack has held high-level management positions with Purdue Pharma, Endo Pharmaceuticals, Novartis, and EKR Therapeutics. He has led training, marketing, and commercial distribution for billion-dollar pain management products and has forged key strategic alliances. By serving on executive boards for SCILEX and ProSolus, Mr Mack has utilized his skills and experience to implement policies relating to corporate governance and overall business strategy. Mr Mack holds an MBA in Pharmaceutical and Healthcare Marketing from Saint Joseph’s University and a BS in Business Management from Charter Oak State College in Newington, CT.
William Pedranti, JD
William Pedranti has more than 10 years of experience serving as senior counsel and as a senior executive at leading biotech and pharmaceutical companies, most recently as Vice President and General Counsel for Spectrum Pharmaceuticals. During Mr Pedranti’s tenure at Spectrum, he oversaw the growth of the company from pre-revenue to $28 million in annual revenue and from 15 employees to 160 employees. Mr Pedranti facilitated equity financing transactions that raised more than $200 million, which supported the acquisition of 8 drug products. Additionally, Mr Pedranti was responsible for out-licensing transactions that generated more than $80 million in upfront fees. Prior to Spectrum Pharmaceuticals, Mr Pedranti provided corporate, transactional, regulatory, and M&A advice to small and large companies in various industries, including life sciences at the international law firm Latham & Watkins LLP. Mr Pedranti received his BS in Business from the University of Southern California and his JD from Georgetown University Law Center.
Kevin HerdeKevin Herde is Executive Vice President and Chief Financial Officer for Sorrento Therapeutics, Inc. where he heads the finance, accounting and investor relations functions. Mr. Herde has over 20 years of progressive experience in finance, accounting and general management. Most recently he was the Vice President of Global Blood Screening and Alliance Management for Hologic, a global healthcare company, with accountability for over 0 million in revenues from a portfolio of businesses within the Hologic Diagnostic Solutions division. These businesses included the global blood screening franchise with Grifols, the industrial testing relationship with Roka Biosciences, the Tepnel Pharma Services CRO business, as well as the prostate cancer diagnostic business. Mr. Herde also served as the divisional business lead for the intellectual property estate via licensing and structuring business partnerships. He joined Hologic in August 2012 after being instrumental in the negotiated sale of Gen-Probe to Hologic for .7 billion. He joined Gen-Probe, a large molecular diagnostic company in April of 2002, assisting Gen-Probe in its IPO in September of 2002 with an initial market capitalization of 0 million. At Gen-Probe he served in numerous finance roles, ultimately as the Vice President of Finance and Corporate Controller. In addition to the leadership of Gen-Probe’s finance and accounting department, he served as a leading executive in the planning, due diligence and execution of multiple acquisitions, divestitures and strategic partnerships, and was an integral leader for the global blood screening collaboration with Novartis (subsequently Grifols). Prior to his 14-year tenure at Gen-Probe / Hologic, Mr. Herde served in multiple management roles in finance for Gateway, the global computer and technology company, and was an Audit Manager for KPMG LLP. Mr. Herde is a CPA and holds a BBA, Business Administration, from the University of San Diego (USD).
George Ng, JDGeorge Ng is Executive Vice President and Chief Administrative Officer for Sorrento Therapeutics, Inc., where he heads the legal, human resources, compliance, quality and intellectual property functions. Prior to joining Sorrento Therapeutics, Mr. Ng held various senior management positions, including General Counsel, Chief Compliance Officer and Chief Intellectual Property Counsel, with publicly-traded, global biotechnology and pharmaceutical companies, including BioDelivery Sciences International, Inc. (NASDAQ: BDSI), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and Alpharma, Inc. (now, a part of Pfizer Inc.). Previously, in private practice, Mr. Ng was a partner in two AMLAW 200 law firms where he had leadership roles, including establishing the life sciences practice group and heading it as the national co-chair. Mr. Ng is also a past President-Elect of the Pan Asian Lawyers of San Diego (PALSD) and was recently appointed to the Leadership Development Committee of the Wake County Bar Association in North Carolina. He is a frequent speaker and noted authority on legal, compliance and business issues in the life sciences, with past speaking engagements at the 2011 BIO International Convention and various pharmaceutical congresses and conferences. Among his multiple awards and commendations, Mr. Ng is a recipient of the 2015 Outstanding 50 Asian Americans in Business Award and past recipient of M&A Advisor’s Top 40 Under 40 Award (in 2012), and, in 2010, MDB Capital recognized Mr. Ng (and the company where he led the intellectual property efforts) for its Best and Brightest Award and as an Astrum Award nominee for a pharmaceutical patent portfolio that he managed and developed. Mr. Ng obtained his J.D. from the University of Notre Dame and a B.A.S. (dual degree) in Biochemistry and Economics from the University of California, Davis.
Not your typical pharma
We’re not just your average pharmaceutical company. We’re a different breed altogether. Ours is a passionate team of talented people working together to make a difference in the world of pain management. Our team-spirited approach ensures a collaborative, engaged, and focused atmosphere where we push thinking further, fostering innovation and fervently pursuing viable solutions for patients and providers through groundbreaking technologies. We believe in the “law of science” and that we’re all entitled to live healthy and pain-free lives—because we’re patients, too. We don’t just seek answers. We seek THE answer. That’s how our team embodies being “Responsible by design.”